Krystal Biotech Inc (KRYS)

Currency in USD
297.90
-7.33(-2.40%)
Closed·
297.900.00(0.00%)
·
Advertisement
KRYS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
295.01306.44
52 wk Range
202.99382.54
Key Statistics
Prev. Close
297.9
Open
302.86
Day's Range
295.01-306.44
52 wk Range
202.99-382.54
Volume
203.29K
Average Volume (3m)
280.42K
1-Year Change
43.0492%
Book Value / Share
48.50
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KRYS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
388.22
Upside
+30.32%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Krystal Biotech Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

11 Buy
1 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 388.22
(+30.32% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Buy380.00+27.56%403.00Maintain03/11/2026
RBC Capital
Buy375.00+25.88%400.00Maintain03/11/2026
Citi
Buy412.00+38.30%416.00Maintain03/11/2026
Citi
Buy416.00+39.64%386.00Maintain15/10/2026
Goldman Sachs
Buy441.00+48.04%-New Coverage24/09/2026

Krystal Biotech Inc Earnings Call Summary for Q3/2026

  • Krystal posted Q3 2026 EPS of $2.05 on revenue of $127.34M, beating estimates of $1.84 and $126.77M; shares fell 5.5% on margin and growth concerns.
  • VYJUVEK revenue rose 30% YoY to $127.3M, with cumulative sales reaching $1.1B; gross margin declined to 94% from 96% due to international sales mix.
  • Company lowered full-year 2026 non-GAAP R&D and SG&A guidance to $155M-$165M from $175M-$195M, citing spending flexibility and efficiency gains.
  • Board authorized $400M share buyback over two years; company holds $1.2B in cash and investments to fund expansion, research, and capital returns.
  • Key pipeline milestones include KB111 data by year-end 2026, KB803 results post-February 2027, and KB407 cystic fibrosis interim data in H1 2027.
Last Updated: 02/11/2026, 14:32
Read Full Transcript

Earnings

Latest Release
02/11/2026
EPS / Forecast
2.05 / 1.84
Revenue / Forecast
127.34M / 126.77M
EPS Revisions
Last 90 days

Compare KRYS to Peers and Sector

Metrics to compare
KRYS
Peers
Sector
Relationship
P/E Ratio
39.2x−3.5x−0.2x
PEG Ratio
3.72−0.360.00
Price/Book
6.1x5.0x2.6x
Price / LTM Sales
18.8x11.2x2.7x
Upside (Analyst Target)
30.3%308.3%66.0%
Fair Value Upside
Unlock36.7%10.8%Unlock

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Employees
295

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
16.30M55.01%4.98B
Other Institutional Investors
13.37M44.99%4.08B
Public Companies & Retail Investors
0.000.00%0.00
Total
29.67M100.00%9.06B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC14.98%4,439,7691,355,151
BlackRock, Inc.11.57%3,427,6451,046,220

People Also Watch

301.71
LGND
-2.29%
453.91
CW
-3.84%
34.54
LAUR
-1.40%
267.85
MYRG
-1.92%
125.85
KYMR
-1.35%

FAQ

What Is the Krystal Biotech (NASDAQ: KRYS) Share Price Today?

The Krystal Biotech stock price today is 297.90 USD.

What Stock Exchange Does Krystal Biotech (KRYS) Trade On?

Krystal Biotech is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Krystal Biotech?

The stock symbol (also called a 'ticker') for Krystal Biotech is "KRYS."

What Is the Current Krystal Biotech Market Capitalisation?

As of today, Krystal Biotech (NASDAQ: KRYS) market cap is 8.83B USD.

What Is Krystal Biotech's (KRYS) Earnings Per Share (TTM)?

The Krystal Biotech EPS is currently 7.66 (Trailing Twelve Months).

When Is the Next Krystal Biotech Earnings Date?

Krystal Biotech's next earnings report will be released on 01/03/2027.

Is KRYS a Buy or Sell From a Technical Analyst Perspective?

Based on today's Krystal Biotech moving averages and other technical indicators, the daily buy/sell signal for KRYS stock is Strong Sell.

How Many Times Has Krystal Biotech Stock Split?

Krystal Biotech has split 0 times. (See the KRYS stock split history page for full effective split date and price information.)

How Many Employees Does Krystal Biotech Have?

Krystal Biotech has 295 employees, based on their latest Companies House report.

What is the current trading status of Krystal Biotech (NASDAQ: KRYS)?

As of 17/11/2026, Krystal Biotech (KRYS) is trading at a share price of 297.90 USD, with a previous close of 297.90 USD. The stock has fluctuated within a day range of 295.01 USD to 306.44 USD, while its 52-week range spans from 202.99 USD to 382.54 USD.

What Is Krystal Biotech (KRYS) Price Target According to Analysts?

The average 12-month price target for Krystal Biotech is 388.22 USD, with a high estimate of 474 USD and a low estimate of 284 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +30.32% Upside potential.

What Is the KRYS Premarket Price?

KRYS's last pre-market stock price is 305.97 USD. The pre-market share volume is 100.00, and the stock has decreased by 0.74, or 0.24%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.